|Bid||1,468.00 x 175400|
|Ask||1,468.50 x 417900|
|Day's Range||1,455.50 - 1,471.50|
|52 Week Range||1,444.00 - 1,745.56|
|PE Ratio (TTM)||37.54|
|Dividend & Yield||1.01 (5.14%)|
|1y Target Est||N/A|
GlaxoSmithKline plc (GSK) along with partner Innoviva reports positive results from a phase III study, evaluating a single inhaler triple therapy in patients with COPD.
GlaxoSmithKline (GSK) is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.
GlaxoSmithKline is an inspired choice for value investors, as it is hard to beat its incredible lineup of statistics on this front.